Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Amlenetug in Healthy Chinese and Caucasian Participants
NCT06258720Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlenetug in multiple system atrophy (MSA) and Parkinson's disease (PD) (2 arms), sponsored by Lundbeck. Primary endpoints: Treatment-emergent adverse events, Anti-drug antibodies and 12 more. Started Mar 2024; status: completed.
02
Drugs
amlenetug
03
Conditions
multiple system atrophy (MSA)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06258720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258720.